Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 4/20 | 0.53 |
| ▸ | STS | P08842 | 5/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.44 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379625 | 0.91 | ALDH1A1 (0.54) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL4712469 | 0.87 | ALDH1A1 (0.52) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL4716931 | 0.85 | ALDH1A1 (0.57) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL4635461 | 0.84 | ALDH1A1 (0.56) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL6249997 | 0.84 | ALDH1A1 (0.56) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL4713688 | 0.84 | ALDH1A1 (0.53) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL5121483 | 0.83 | ALDH1A1 (0.57) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL31282736 | 0.83 | ALDH1A1 (0.57) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL25390329 | 0.82 | USP30 (0.59) | ALDH1A1HTTNPC1MAPTMAPK1 | |
| SCHEMBL22521596 | 0.82 | ALDH1A1 (0.56) | ALDH1A1HTTNPC1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1304382-C | Novel P2X for use in the treatment of inflammatory, immune or cardiovascular diseases7Receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-14 | — | — | CN | disclosed |
| US-6812226-B2 | FOR THERAPY OF RHEUMATOID ARTHRITIS, EFFECTING IMMUNOSUPPRESSION | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | disclosed |
| EP-1242396-B1 | NEW P2X 7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| CN-1434811-A | Novel P2X for use in the treatment of inflammatory, immune or cardiovascular diseases7Receptor antagonists | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | disclosed |
| US-20030040513-A1 | P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | ASTRAZENECA AB (SE) | 2003-02-27 | — | — | US | disclosed |
| EP-1242396-A1 | NEW P2X 7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044213-A1 | NEW P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISEASES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040513-A1 | P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases | P2RX1, P2RX2, P2RX3 | ALDH1A1 2046/4885HTT 4031/4885NPC1 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.